Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration

Małgorzata Nita
Katarzyna Michalska-Malecka
Urszula Mazurek
Małgorzata Kimsa
Barbara Strzałka-Mrozik
Andrzej Grzybowski

Background:
We know the influence of the intravitreal anti-vascular endothelial growth factor (VEGF) injections on the choroidal neovascularization in the course of exudative age-related macular degeneration (AMD). However, the influence of the ranibizumab therapy in question on the extracellular matrix (ECM) remains unknown. We aimed to estimate the influence of Lucentis intravitreal injections on the gene expression of structural components of the extracellular matrix in patients with neovascular AMD.

Material/Methods:
Patients with subfoveal localization of neovascularization in AMD, which was clinically active and observed using optical coherence tomography, were treated with ranibizumab (0.5 mg/0.05 mL) in accordance with the PrONTO scheme. Total RNA was extracted from peripheral blood mononuclear cells, and an oligonucleotide microarray technique enabled comparison of the expression level of genes encoding collagens, elastin, and laminins in AMD patients compared to control subjects.

Results:
After 3 intravitreal injections of ranibizumab (Lucentis), COL1A1 and COL6A1 genes showed increased expression, whereas decreased expression mainly occurred for the following genes: COL4A5, COL11A1, COL4A6, LAMB4, and LAMC2.

Conclusions:
Anti-VEGF local therapy influences the gene expression of structural components of the ECM as measured from blood samples. The loading dose of ranibizumab for the retina changes the expression of collagen and laminin genes, but does not influence the expression of the elastin gene.

MeSH Keywords:
Neovascular (Exudative) Age-Related Macular Degeneration • Ranibizumab • Extracellular Matrix • Bruch’s Membrane • Collagen • Elastin • Laminin

Abbreviations:
AMD – age-related macular degeneration; CNV – choroidal neovascularization; ECM – extracellular matrix; MMP – matrix metalloproteinase; RPE – retinal pigment epithelium; TIMP – tissue inhibitor of metalloproteinase; VEGF – vascular endothelial growth factor

Full-text PDF: http://www.medscimonit.com/download/index/idArt/890031
**Background**

Age-related macular degeneration (AMD) is the main cause of practical and irreversible central blindness (scotoma in the central visual field makes impossible the following: reading and writing, stereoscopic vision, and recognition of colors and details) in patients after the age of 50 years in industrialized countries in Europe and North America [1,2]. In 10% to 15% of these patients, advanced (late) AMD occurs in the exudative form, characterized by the presence of choroidal neovascularization (CNV) resulting from angiogenesis and the pathological proliferation of choroid vessels in the extracellular matrix (ECM) and under the retina [1,2]. The pathology of AMD starts the dysregulation of metabolic processes at the level of retinal pigment epithelium (RPE) cells; however, the area of these disorders is the extracellular matrix, which is Bruch’s membrane [1–3]. Bruch’s membrane, the main components of which are collagens, elastin, and laminins, constitutes a sort of scaffold for RPE cells, a physical barrier for the passage of RPE cells and the endothelial tissue of blood vessels, and the interface regulating the diffusion of nutritional molecules between the retina and the choroid [3,4]. In the pathogenesis of CNV/AMD, a key role is played by vascular endothelial growth factor-A (VEGF-A) [5,6]; however, changes in the ECM are also necessary in order to create the conditions for adhesion of the proliferating and migrating endothelial tissue and for the expansion of the newly created vessels [7]. Intravitreal injections of ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA), an antigen-binding fragment of a recombinant, humanized monoclonal antibody, inhibit all of the known biologically active forms of VEGF, which in turn inhibits the proliferation of endothelial tissue, vessel leakage, and angiogenesis [8–11]. Ranibizumab reduces edema in the central retina [9]: in 90% to 95% of patients, it stabilizes visual acuity, and in one-third of patients, it improves it [8,9]. It is an effective cure for CNV/AMD [8,10,12]; however, it is not devoid of adverse effects [10,13,14].

To date, neither the general nor the regional effects of Lucentis injections on the ECM in patients with CNV/AMD have been described, and to the best of our knowledge, this is the first study to examine these effects. Our aim was to estimate the influence of the loading dose of ranibizumab (Lucentis) on the expression of collagen, elastin, and laminin genes in patients with the exudative form of AMD.

**Material and Methods**

**Material**

Patients with the active, exudative form of AMD qualified for participation in the study if they met the criteria presented in Table 1.

**Methods**

**Ophthalmological tests**

The following ophthalmological tests were given to each participant: (1) best corrected visual acuity on the ETDRS charts; (2) indirect biomicroscopy in mydriasis (+78 D lens; Volk Optical,

---

**Table 1.** Inclusion and exclusion criteria for patients with active CNV qualified for intravitreal injections of ranibizumab.

| Inclusion criteria                                      |
|----------------------------------------------------------|
| – age ≥60 years                                          |
| – interview (decrease in BCVA, metamorphopsia) no longer than 3 months |
| – BCVA 20/25 to 20/200 Snellen equivalent                |
| – CNV activity in biomicroscopy (central edema of retina, hard exudates, hemorrhages), OCT (hyperreflectivity characteristic for CNV, presence of SRF and/or IRF), FAG/ICG (vascular leakage) |
| – each of the angiographic CNV subtypes of subfoveal localization (predominantly classic, minimally classic, fibrovascular RPE detachment, leakage of unknown source) |
| – no previous CNV therapies: anti-VEGF injections (Lucentis, Avastin, Macugen), photodynamic therapy with verteporfin, laser therapy, steroid therapy (triamcinolone) |
| – written consent for both the Lucentis injections and participation in the study |

| Exclusion criteria                                      |
|----------------------------------------------------------|
| – polypoidal choroidal vasculopathy, retinal angiomaticous proliferations |
| – idiopathic CNV as well as CNV in cases of high myopia, angioid streaks, inflammation, or infection (histoplasmosis, sarcoidosis, multifocal choroiditis, punctuate inner choroidopathy), choroid tumors (melanoma, hemangioma, osteoma), injuries (choroidal rupture, laser photocoagulation), retinal vein occlusion |
| – coexisting diabetic maculopathy, epiretinal membrane |

BCVA – best corrected visual acuity; CNV – choroidal neovascularization; FAG – fluorescein angiography; ICG – indocyanine green angiography; IRF – intraretinal fluid; OCT – optical coherence tomography; RPE – retinal pigment epithelium; SRF – subretinal fluid; VEGF – vascular endothelial growth factor.
analyzed and recorded using the 1D Bas-Sys gel documentation system (Biotech-Fisher, Perth, Australia). Total RNA concentration was determined by spectrophotometric measurement in 5-μL capillary tubes using the GeneQuant II RNA/DNA Calculator (Pharmacia Biotech, Cambridge, UK).

**Oligonucleotide microarray analysis**

All samples were selected for microarray analysis. Analysis of the expression profile of genes related to the selected ECM components: collagens, laminin, and elastin in samples collected before (3 samples) and after (5 samples) ranibizumab intravitreal injection, was performed by using commercially available oligonucleotide microarrays of HG-U133A (Affymetrix, Santa Clara, CA) according to the manufacturer's recommendations. Each gene chip contained 22,238 probe sets corresponding to more than 18,400 transcripts and 14,500 well-characterized human genes. Approximately 8 μg of total RNA was used for complementary cDNA synthesis using the SuperScript Choice System (GIBCO BRL Life Technologies, Carlsbad, CA). During the next step, complementary DNA was used as a template to produce biotin-labeled complementary RNA (cRNA) with the BioArray HighYield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY). Complementary RNA was purified on RNeasy Mini Kit columns (Qiagen GmbH, Hilden, Germany). Next, the biotin-labeled cRNA was fragmented by using the GeneChip Sample Cleanup Module (Qiagen) and hybridized with the HG-U133A microarray (Affymetrix). The hybridized cRNA were stained with streptavidin phycoerythrin conjugate and scanned using a GeneArray Scanner G2500A (Agilent Technologies, Santa Clara, CA). The scanned data were processed for signal values using Microarray Suite 5.0 software (Affymetrix). The results obtained were normalized with RMAExpress software (Robust Multi-chip Average).

**Statistical analysis**

Microarray data analysis was performed with the GeneSpring 12.0 platform (Agilent Technologies UK Ltd., South Queensferry, UK) to identify transcriptome differences between the control and the study groups. The oligonucleotide microarrays of Affymetrix HG-U133A enabled analysis of 22,283 mRNA transcripts. For further study, we selected only 98 transcripts from the Affymetrix NetAffx Analysis Center database (http://www. affymetrix.com/analysis/index.affx). Normalized data were used to compile a list of 7 genes, the expression of which appeared to be up- or down-regulated by an arbitrary cutoff of at least 2-fold. Significant differential gene expression was identified by a 2.0-fold change at P<0.05. The results obtained through the oligonucleotide microarray technique were grouped with the hierarchical clustering method using the Euclidean distance measure.

The study was approved by the Bioethics Committee of the Medical University in Katowice, in accordance with the
Table 2. Characteristics of patients with CNV/AMD treated with intravitreal injections of ranibizumab and control group patients with CNV/AMD.

|                        | Treated group N=5 eyes | Control group N=3 eyes |
|------------------------|------------------------|------------------------|
| **Sex**                |                        |                        |
| Female                 | 3 (60%)                | 2 (67%)                |
| Male                   | 2 (40%)                | 1 (33%)                |
| **Age (y) Mean (SD)**  | 76.80 (6.10)           | 75.33 (2.31)           |
| **Range**              | 72.0–86.0              | 74.0–78.0              |
| **Eyes**               |                        |                        |
| Right                  | 3 (60%)                | 2 (67%)                |
| Left                   | 2 (40%)                | 1 (33%)                |
| **BCVA (log MAR)**     |                        |                        |
| before therapy Mean (SD)| 0.78 (0.35)           | 0.73 (0.25)            |
| Range                  | 1.0–0.2                | 1.0–0.5                |
| after therapy Mean (SD)| 0.44 (0.19)           |                        |
| Range                  | 0.7–0.2                |                        |
| **CNV subfoveal localization** | 5 (100%)             | 3 (100%)              |
| **CNV component:**     |                        |                        |
| Minimally classic      | 1 (20%)                | 3 (100%)               |
| Occult with no classic | 4 (80%)                | 1 (33%)                |
| fibrovascular RPE detachment | 1 (20%)             | 2 (67%)                |
| leakage of unknown source | 3 (60%)              |                        |
| **Central retinal thickness before/after therapy µm Mean (SD)** | 319.1 (103.9)/233.4 (77.6) | 337.5 (118.3) |
| **Lens status**        |                        |                        |
| Phakic                 | 5 (100%)               | 2 (67%)                |
| Pseudophakic           |                        | 1 (33%)                |
| **IOP mmHg Mean (SD)** | 15 (4.30)              | 16.33 (2.31)           |
| **General disorders**  |                        |                        |
| AH                     | 2 patients             | 2 patients             |
| IHD                    | 2 patients             | 1 patient              |
| Osteoporosis           | 1 patient              |                        |
| Hypothyreosis          |                        | 1 patient              |
| **Diet supplementation** | All patients         | All patients           |
| **Post-injection complications** | None local and general |                        |

AH – arterial hypertension; AMD – age-related macular degeneration; BCVA – best corrected visual acuity; CNV – choroidal neovascularization; IHD – ischemic heart disease; IOP – intraocular pressure; logMAR – logarithm of the minimum angle of resolution; RPE – retinal pigment epithelium; SD – standard deviation.

Declaration of Helsinki regarding medical research involving human subjects. The study and its purpose were explained to each participant or his or her legal guardian, who gave written informed consent.

Results

The characteristics of the patients participating in the test are shown in Table 2.

Discussion

Ranibizumab (Lucentis) is a biological medication, with regional and general activity, as can be demonstrated by its...
Table 3. Change in expression of collagen and laminin genes after three injections of ranibizumab.

| Name of probe | Gene       | Name of gene                  | FC  | *P   |
|--------------|------------|-------------------------------|-----|------|
| 202312_s_at  | COL1A1     | Collagen, type I, alpha 1     | 2.19↑| 0.0068|
| 212938_at    | COL6A1     | Collagen, type VI, alpha 1    | 2.41↑| 0.0153|
| 213110_s_at  | COL4A5     | Collagen, type IV, alpha 5    | 2.09↓| 0.0001|
| 216622_at    | LAMB4      | Laminin, beta 4               | 2.14↓| 0.0005|
| 202267_at    | LAMC2      | Laminin, gamma 2              | 2.24↓| 0.0038|
| 204320_at    | COL11A1    | Collagen, type XI, alpha 1    | 2.74↓| 0.0011|
| 213992_at    | COL4A6     | Collagen, type IV, alpha 6    | 3.32↓| <0.0001|

FC – multiple of difference in fluorescence signals, statistical importance: * P<0.05, t test; ↑ overexpression of gene, ↓ underexpression of gene.

pharmacokinetics [6,10,11,17]. Injected into the vitreous body, it penetrates the whole retina to the level of neovascularization. Next, it undergoes slow absorption into the circulatory system: its concentration in the serum is approximately 90 000–140 000 times less and it decreases simultaneously with the decrease in its level in the vitreous body [6]. In patients with CNV/AMD, after multiple injections, there was less than 11 ng/ml of ranibizumab in the serum, a level that blocks the biological activity of VEGF-A [6]. After being catabolized in the kidneys, the medication is eliminated in the urine [17]. Ranibizumab is a protein, which in approximately 1% to 8% of treated patients stimulates antibody production; antibodies may reduce its therapeutic effectiveness, enter into reactions with endogenic proteins, and cause anaphylactic reactions [18]. Apart from its local effects, it can also cause general adverse effects: hypertension, nasopharyngitis, headache, arthralgia, stroke, cardiac infarction, hemorrhage, thrombosis, and emboli, and even death that is related or unrelated to the blood vessels [10,19]. Ranibizumab also influences the ECM, as shown in our study. Under the influence of the loading dose of Lucentis, the genes coding collagen type I (gene COL1A1) and collagen type VI (gene COL6A1) were overexpressed.

An increase in the amount of interstitial collagen type I, being the most abundant component of the ECM, may favor cell adhesion, as well as maintenance of tension and mechanical endurance of the collagen fibers of various tissues, such as bones, joints, and skin [20,21]. Theoretically, this increase may also favor the rebuilding process of Bruch’s membrane after being degraded by neovascularization, since the structural and functional rebuilding of the collagen layers can improve the mechanical stability of Bruch’s membrane, facilitate RPE cell adhesion, transport nutrients and products of metabolism, and transmit signals.

Increased interstitial collagen type I may also have a negative impact on the condition of the retina and destroy the effects of regional anti-VEGF therapy, because collagen type I induces genes involved in angiogenesis, has strong activity in the process of angiogenesis, and facilitates the development of CNV [22]. Increased collagen I occurring after injections of Lucentis may stimulate and sustain angiogenesis, and, as has been shown by Nguyen [23], in the case of illness, activate 2 endopeptidases crucial to the process: gelatinase A (matrix metalloproteinase-2; MMP-2) and membrane-type metalloproteinase-1 (MMP-14) [23]. MMP-2, the most abundant and significant metalloproteinase synthesized by RPE and endothelial cells, digests the main structural element of basement membranes (ie, collagen IV); moreover, similar to interstitial collagenases, it digests stromal collagen type I and V, as well as digesting gelatin, elastin, laminin, and fibronectin [23–25]; plays a key role in Bruch’s membrane remodeling [26–28]; and is crucial in angiogenesis [23] and CNV/AMD [23,29]. It also promotes the activation of latent interstitial collagenases and their ability to degrade stromal collagen [30]; interstitial collagen digestion produces gelatin (denatured collagen), which acts as a specific substrate for MMP-2 [23]. MMP-14 activates MMP-2 directly and by mediation of tissue inhibitor of metalloproteinase-2 (TIMP-2) in a 3-molecule complex: pro-MMP-2/TIMP-2/active MMP-14 [23]. MMP-14 influences the ECM by activating MMP-2 in the range of the 3-molecule complex, but it can also direct the degradation of interstitial collagen type I, II, and III [25,31]. ECM digestion is necessary to the deposition and breakdown of choriocapillaris basement membrane, to opening space to endothelial cell invasion, to capillary tube formation and sprouting of new vessels, and to the mobilization of ECM receptor shedding and activation of pro-/anti-angiogenic growth factors to enable cell migration and proliferation [32]. By activating both of the metalloproteinases having such a broad spectrum of activity, collagen I triggers the so-called vicious cycle of auto-degradation, as well as sustaining pathological angiogenesis for a lengthy period until the endothelial tissues do not shape their own base membranes, which in turn becomes a barrier for contact with collagen and further stimulation by both enzymes [23].
Moreover, neovascularization sustains pathological angiogenesis, while leakage of its various components to the basal laminar deposits, located under the RPE layer (ie, the basal laminar deposits and soft drusen, as well as in the area of 2 collagen layers and elastic layer of Bruch’s membrane), favors untypical polymerization of molecules into aggregates similar to ribbons and long fibers of collagen [33]. Accumulation of the new structures thickens the basal laminar deposits much more, which in turn worsens the supply of the RPE/photoreceptors complex with nutrients and oxygen, favoring hypoxia and sustaining neovascularization [33].

An increased expression of genes of collagen type VI, a component of the basement membranes [34], occurring after the injections, may be profitable because it increases the amount of a factor that favors the adhesion of cells to the basement membranes, as well as the interactions in the range of the ECM throughout the organism and in the retina [34]. On the other hand, it may theoretically worsen the retina’s condition in the treated and in the adjacent eye, since it causes enlargement of basal laminar deposits (BLamD) and soft drusen (SD) and, through them, may favor pathological angiogenesis [35–37]. BLamD that are larger than 25 μm become clinically visible SD, which intensify the process of lipofuscinogenesis in the RPE, worsen RPE cell metabolism and their ability to supplement the photoreceptors, and separate RPE cells from the internal collagen layer of Bruch’s membrane [35,38,39]. On the other hand, SD bigger than 125 μm and confluent is a risk factor for the development of advanced forms of AMD, which means geographical atrophy or neovascularization within the next 5–10 years [40,41].

Because of the loading dose of ranibizumab, the genes coding collagen type IV (COL4A5, COL4A6) and type XI (COL11A1), as well as the genes coding beta–lamin (LAMB4) and gamma-lamin (LAMC2), undergo a silencing process. The genes COL4A5 and COL4A6 are linked in the genome [42]. Moreover, both underwent a silencing process in our analysis; however, the COL4A6 gene showed the highest loss of expression. A decrease in collagen type IV after injection of Lucentis may be considered disadvantageous for the following reasons.

From a structural point of view, the decrease in the amount of the main and structural components of the basement membranes may disintegrate, as well as destabilize, the basement membranes in the entire body (including the basement membranes of the RPE cells and the choroid endothelial tissues) and it may distort the cells’ adhesive properties to the basement membranes [43–45].

In the eyes, in the case of the neovascular form of AMD, the loss of collagen type IV may also be theoretically undesirable because of its anti-angiogenic properties [46–48]. Collagen type IV acts anti-angiogenically on different levels (mechanisms, manners). It can inhibit both proliferation and migration of the endothelial tissues in the eye tissues [47]; in the process of adhesion, it binds with the non-integrin and integrin receptors of the cell (mainly β1 integrins), as some of them work in an anti-angiogenic manner [49]; and it participates in homeostasis [46,48].

In patients undergoing local anti-VEGF therapy, apart from the changes in the area of the vitreous body (over the age of 40 years, it appears as gradual liquefaction of the vitreous body’s gel-synchnosis senilis) [50,51], overlap also occurs in the changes resulting from the numerous injections, because the loading dose of the medication, with time, is combined with re-injections, which are dependent on relapse/lasting of subretinal or intraretinal fluid in OCT, loss of 5 lines on the ETDRS chart, and/or angiographically proven enlargement of CNV [15,16].

Development of persistent vitreomacular attenuation may cause a macular hole or cystoid macular edema, together with the relapse of metamorphopsia; such cases are not a result of CNV relapse, but a consequence of the changes within the vitreous body [52–54].

The ECM of the eye contains numerous components typical for hyaline cartilage, namely, collagen type II, VI, IX, and XI [34,43,55–57]. After the application of 3 anti-VEGF injections in our material, a decrease appeared in the expression of the genes of collagen type XI (COL11A1), which is closely related both structurally and actively to collagen type V, regardless of the fact that they have different localizations in the genome [55–57]. Collagen type V and XI constitute approximately 10% of the collagen fibers of the vitreous body [57,58]. Mutations of the gene COL11A1 distort fibrillogenesis, causing the formation of rare, thickened, and irregular collagen fibers of the vitreous body, which are typical for the Stickler and Marshall syndrome [59,60].

Loss of collagen XI, after the loading dose of Lucentis, may theoretically distort renewal of the vitreous body after it is exposed to numerous iatrogenic injuries. On the other hand, after the injections occurred, the expression of the collagen VI gene (COL6A1) increased, which, next to collagens being coded by the genes COL6A2 and COL6A3, also belongs to the so-called eye-cartilage-collagens [34,43,55–57]. Collagen VI stabilizes the gel-like structure of the vitreous body by binding its various fibers with hyaluronic acid [50,55]. Increased expression of collagen VI may, theoretically, favor both stabilization and renewal of the vitreous body that is changed by the injections, as well as limiting the decreased expression of the collagen XI gene.

Theoretically, the change of expression of collagen type I, IV, and VI genes after loading dose of ranibizumab, influences in the eye not only by the condition of Bruch’s membrane, but also the ECM in trabecular meshwork, sclera, and lamina cribrosa.
Collagen is the main structural component and therefore, contributes to the mechanical properties, organization, and the shape of these tissues, and it plays an important role in glaucoma pathogenesis [61]. Therefore, the change of expression of collagen genes may hypothetically favor glaucoma development in patients being treated with Lucentis, which can be demonstrated by the following study results: 1) collagen type I, the main component of ECM in the trabecular meshwork and uveoscleral aqueous humor outflow pathways, may be involved in increased aqueous humor outflow resistance in trabecular meshwork and elevation of intraocular pressure; 2) changes of synthesis of type IV collagen have been found in glaucomatos trabecular meshwork; and 3) collagen types I, IV, and VI (as well as types III and V) constitute the main composition in the lamina cribrosa, and the content and/or the composition of the collagen molecules in the lamina cribrosa is significantly changed in glaucoma [61]. However, the above hypothesis needs further and detailed study.

The loading dose of Lucentis caused decreased expression of beta-laminin (LAMB4) and gamma-laminin (LAMBC2). Laminin, next to collagen type IV, is the key structural component of basal membranes [4,62], and is classified as a so-called big-sized component of the basement membrane [62]. Laminin fills up the eyelets in the 3-dimensional network of collagen IV, to which it joins directly or via bridges (entactin/nidogen) [48,63] and joins the cell surface via surface receptors [4,48,64]. Laminin initiates the process of membrane formation and is therefore indispensable [4,44,64], in contrast to collagen IV, which despite its ubiquity and abundance, does not initiate the formation of basement membranes, but does play a role in supporting their structure [44].

Decreased laminin gene expression after the injections may not be beneficial, both generally and regionally, and may favor neurological defects or disorders of muscle, skin, or kidneys [63,64].

A decrease in the factor necessary for building the basement membranes may theoretically limit their formation, including the restoration of basement membranes in RPE cells, as well as in the endothelial cells of the choroid, which are damaged in the process of angiogenesis. It may disturb the process of cell adhesion and the passing of signals in the range of the ECM in the entire body and in Bruch’s membrane.

On the other hand, the process of neovascularization requires a certain change in the ECM in such a way that the migrating endothelial cells can adhere, and moreover, not undergo the process of apoptosis. Such a change in the ECM is regulated at various levels by many factors, such as laminin (mainly LAM-1) [7,65]. A decrease in the amount of laminin after the injections (in this context) can be beneficial, since it may not facilitate the pathological rebuilding of Bruch’s membrane; moreover, it can hamper the adhesion of the migrating endothelial cells and therefore limit the development of CNV [66].

Conclusions

Apart from its regional influence, ranibizumab also works generally since it changes the gene expression of structural components of the ECM, as measured in blood levels (i.e., collagens and laminins); however, it does not influence the expression of elastin genes. Changes in the structural collagens in Bruch’s membrane under the influence of ranibizumab (increased collagen I and decreased collagen IV) may theoretically favor re-lapse of neovascularization and re-injections in the treated eye; moreover, this may theoretically accelerate the development of the exudative phase of AMD in the adjacent eye, which has so far represented only the early symptoms of AMD. The beneficial effects of the therapy in question may be the decrease in laminin, which has pro-adhesive activities. Ranibizumab also changes the gene expression of the structural collagens of the vitreous body (i.e., it increases the gene expression of collagen VI and decreases the gene expression of collagen XI). The necessity of repeating the anti-VEGF injections may not only result from the natural tendency of the vessels to recanalize, including pathological vessels, but may also be connected to changes in ECM structure, which favors the development of CNV, mainly in terms of the changed amount of collagen type I (which favors the development of CNV and stimulates the activity of 2 strong pro-angiogenic metalloproteinases characterized by a wide spectrum of activity) and collagen type IV (because of its anti-angiogenic properties).

Acknowledgements

We thank Barbara Every, ELS, of BioMedical Editor, for language editing assistance.

The above study was entitled “Expression pattern of extracellular matrix (ECM) components after ranibizumab treatment of neovascular age-related macular degeneration (AMD)” and was presented as a free paper, at 09-26-2013, during 13th Euretina Congress in Hamburg, BRD.

Competing interests

No competing interests. All authors declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
References:

1. Wong TY, Chakravarthy U, Klein R et al: The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology, 2008; 115: 116–26

2. De Jong PT: Age-related macular degeneration. N Engl J Med, 2006; 355: 1474–85

3. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol, 2004; 122: 598–614

4. Agmael TV, Bruckner-Tuderman L: Basement membranes and human disease. Cell Tissue Res, 2010; 339: 67–188

5. Penn JS, Madan A, Caldwell RB et al: Vascular endothelial growth factor in eye disease. Prog Retin Eye Res, 2008; 27: 331–7

6. Bhushal RB: Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol, 2006; 90: 1542–47

7. Li J, Zhang YP, Kirner RS: Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech, 2003; 60: 107–14

8. Kang S, Roh YJ: Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration. Jpn J Ophthalmol, 2011; 55: 123–27

9. Mitchell P, Korobelnik JF, Lanzetta P et al: Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trias. Br J Ophthalmol, 2010; 94: 2–13

10. Lucentis FDA official information, side-effects and uses. Available at http://www.drugs.com/pro/lucentis.html. Accessed on 12 Feb 2008

11. Blick SK, Keating GM, Wagstaff AJ: Ranibizumab. Drugs, 2007; 67: 1199–206

12. Figurska M: Retinal pigment epithelial tears following ranibizumab therapy. Br J Ophthalmol, 2009; 93: 1324–8

13. Rahman R, Goverdhan S, Lochhead J: Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularisation. Clin Experiment Ophthalmol, 2009; 37: 384–88

14. Itoh M, Takei J, Karasawa J: Protein expression in cultured retinal pigment epithelial cells grown on type I collagen. Invest Ophthalmol Vis Sci, 2005; 46: 3311–20
51. Wang J, McLeod D, Henson DB, Bishop PN: Age dependent changes in the basal retino-vitreous adhesion. Invest Ophthalmol Vis Sci, 2003; 44: 1793–800

52. Clemens CR, Holz FG, Meyer CH: Macular hole formation in the presence of a pigment epithelial detachment after three consecutive intravitreal anti-vascular endothelial growth factor injections. J Ocul Pharmacol Ther, 2010; 26: 297–99

53. Robison CD, Krebs I, Binder S et al: Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol, 2009; 148: 79–82

54. Meyer CH, Mennel S: Vitreomacular traction, macular hole formation, and subfoveal choroidal neovascularization in a patient with age-related macular degeneration. Eye, 2006; 20: 1090–92

55. Bishop PN, Ayad S, Reardon A et al: Type VI collagen is present in human and bovine vitreous. Graefe’s Arch Clin Exp Ophthalmol, 1996; 234: 710–13

56. Bishop PN, Crossman MV, McLeod D, Ayad S: Extraction and characterization of tissue forms of collagen types II and IX from bovine vitreous. Biochem J, 1994; 299: 497–505

57. Mayne R, Brewton RG, Mayne PM, Baker JR: Isolation and characterization of the chains of type V/type XI collagen present in bovine vitreous. J Biol Chem, 1993; 268: 9381–86

58. Fichard A, Kleman JP, Ruggiero F: Another look at collagen V and XI molecules. Matrix Biol, 1994; 14: 515–31

59. Richards AL, Baguley DM, Yates IRW et al: Variation in the vitreous phenotype of Stickler syndrome can be caused by different amino acid substitutions in the X position of the type II collagen Gly X-Y triple helix. Am J Hum Genet, 2000; 67: 1083–94

60. Griffith AJ, Sprunger LK, Sinko-Osada DA et al: Marshall syndrome associated with a splicing defect at the COL11A1 locus. Am J Hum Genet, 1998; 62: 816–23

61. Huang W, Fan Q, Wang W et al: Collagen: A potential factor involved in the pathogenesis of glaucoma. Med Sci Monit, 2013; 19: 237–40

62. Volonghi I, Pezzini A, Del Zotto E et al: Role of COL4A1 in basement-membrane integrity and cerebral small-vessel disease. The COL4A1 Stroke Syndrome. Curr Med Chem, 2010; 17: 1317–24

63. McKee KK, Harrison D, Capizzi S, Yurchenco PD: Role of laminin terminal globular domains in basement membrane assembly. J Biol Chem, 2007; 282: 21437–47

64. Miner JH: Laminins and their roles in mammals. Microsc Res Tech, 2008; 71: 349–56

65. Patarroyo M, Tryggvason K, Virtanen I: Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol, 2002; 12: 197–207

66. Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med, 2002; 8: 918–21